What Is on the Live Vaccines List and Who Should Avoid Them?

Live vaccines use a weakened but still living form of a virus or bacterium to trigger immunity. The major live vaccines in routine use today include MMR (measles, mumps, rubella), varicella (chickenpox), rotavirus, the nasal-spray flu vaccine, oral polio, yellow fever, BCG (tuberculosis), and oral typhoid. Each contains a pathogen that has been deliberately hobbled so it can replicate just enough to train the immune system without causing full-blown disease. That replication is both their greatest strength and the source of most of the safety questions surrounding them.

The Complete Roster of Live Vaccines

Not every vaccine on the routine schedule is a live vaccine, so knowing which ones are matters for anyone who is pregnant, immunocompromised, or caring for someone who is. Here is the full list of live vaccines currently licensed and in widespread use globally:

MMR: Covers measles, mumps, and rubella. Given as two doses in childhood in most countries. Often combined with varicella as MMRV.
Varicella: Protects against chickenpox. Two doses for children, or two doses for adults who never had the disease.
Rotavirus: An oral vaccine given to infants in two or three doses depending on the brand (Rotarix or RotaTeq). Prevents severe diarrheal illness.
LAIV (FluMist): The nasal-spray influenza vaccine, approved for healthy individuals aged 2 through 49 in the United States. Not the same as the standard flu shot, which is inactivated.
Oral polio (OPV): Still used in many countries for mass immunization campaigns, though most high-income countries have switched to the inactivated injectable version (IPV).
Yellow fever: A single-dose vaccine required for travel to endemic regions in Africa and South America. One of the oldest live vaccines still in use.
BCG: The tuberculosis vaccine, given at birth or in early childhood in countries where TB is common. Rarely used in the United States but standard in much of the world.
Oral typhoid (Ty21a): A capsule-based vaccine for typhoid fever, typically taken as four doses over a week.
Smallpox and mpox (JYNNEOS/ACAM2000): ACAM2000 is a replicating vaccinia virus vaccine; JYNNEOS is a non-replicating modified vaccinia Ankara. ACAM2000 is the live replicating option, used in limited populations.
Adenovirus types 4 and 7: An oral live vaccine used exclusively by the U.S. military to prevent respiratory illness in recruits.

A few older live vaccines, such as the intranasal anthrax vaccine and certain dengue vaccines (Dengvaxia uses a live chimeric virus), sit at the fringes of this list because their use is restricted to specific populations or regions. The shingles vaccine Shingrix, by contrast, is not live; it replaced the older live-virus shingles vaccine Zostavax, which was pulled from the U.S. market in 2020.

How Live Vaccines Produce Immunity

A live vaccine works by mimicking a natural infection on a small scale. The weakened pathogen enters your body, replicates in limited quantities, and your immune system mounts a response to it just as it would to the real thing. This replication is the key distinction from inactivated or subunit vaccines, which deliver dead or fragmented pieces of a pathogen that cannot grow inside you. Because a live vaccine actually infects you with a tame version of the bug, it tends to activate a broader range of immune defenses, including mucosal immunity in the nose and gut.

The nasal-spray flu vaccine illustrates this well. The virus strains in FluMist have been engineered to replicate efficiently at the cooler temperatures found in the nasal passages (around 25°C) but poorly at normal body temperature, so they stay confined to the nose and upper airway rather than spreading into the lungs or bloodstream.¹ That localized replication triggers strong secretory IgA antibody production in the mucosal lining, which is the first barrier a real flu virus would encounter. In a large trial in children, the nasal-spray vaccine showed about 93 percent efficacy against culture-confirmed influenza.² In adults, the picture is more nuanced: the live nasal vaccine induces stronger mucosal IgA than the injected inactivated shot, but weaker serum antibody responses.³ This is why the nasal spray has generally performed better in young children than in adults who already carry some pre-existing immunity.

Why MMR Immunity Lasts So Long

One of the marquee advantages of live vaccines is durability. The MMR vaccine is a prime example. A systematic review and meta-analysis in The Lancet Infectious Diseases estimated seroconversion rates of roughly 96 percent for measles, 93 percent for mumps (excluding the weaker Rubini strain), and 98 percent for rubella after vaccination.⁴ The same analysis found that antibody levels wane slowly, with annual decline rates that are modest enough to keep most people protected for decades.

Long-term follow-up studies bear this out. One study tracking children who received MMR-containing vaccines found that antibodies against measles and rubella declined moderately over time but remained well above the threshold for protection at least ten years after vaccination, while mumps antibody levels stayed relatively stable across the same period.⁵ Earlier work showed antibody persistence without substantial decline for up to eight years after mumps vaccination and six years after measles vaccination, the longest periods tested at the time, with patterns closely resembling those after natural infection.⁶ This durability is a direct consequence of the vaccine virus replicating inside the body and engaging the immune system the way a real infection would, creating deep immunological memory.

Rotavirus and the Intussusception Question

Rotavirus vaccines (Rotarix and RotaTeq) are both live oral vaccines given to infants in the first months of life. They replaced an earlier rotavirus vaccine, RotaShield, which was pulled from the market in 1999 after it was linked to a small increased risk of intussusception, a serious condition where part of the intestine folds in on itself. That history has understandably made parents and clinicians pay close attention to the safety of the current versions.

Post-marketing surveillance continues to track intussusception rates. A study following Rotarix use in Afghanistan over four years found no increased risk of intussusception in the three weeks after either the first or second dose.⁷ Some larger studies in other countries have detected a very small excess risk in the week following the first dose, on the order of one to two additional cases per hundred thousand vaccinated infants. The consensus among global health authorities is that this tiny risk is far outweighed by the prevention of severe rotavirus gastroenteritis, which kills hundreds of thousands of children worldwide each year.

Yellow Fever Vaccine and Rare but Serious Reactions

The yellow fever vaccine (17D strain) is one of the most effective vaccines ever developed. A single dose provides long-lasting, probably lifelong immunity for the vast majority of recipients. But it also carries one of the highest rates of serious adverse events among vaccines in current use. The most feared complication is vaccine-associated viscerotropic disease (YEL-AVD), in which the vaccine virus replicates uncontrollably and causes organ failure resembling severe yellow fever itself.

Research on YEL-AVD cases points to defects in the early innate immune response as a common thread. Patients who develop viscerotropic disease tend to show high virus levels early on, elevated inflammatory cytokines, and severely reduced platelet counts, all signs that the body’s first line of defense failed to contain the vaccine virus before the adaptive immune system could catch up.⁸ A European case series found that fatal YEL-AVD showed a cytokine profile strikingly similar to that of actual yellow fever, with high levels of inflammatory markers, while milder cases displayed the same pattern at lower intensity.⁹ The risk is highest in people over 60 and those with thymus disorders, which is why screening before yellow fever vaccination is taken seriously.

BCG and the Surprising “Off-Target” Effects

BCG, the tuberculosis vaccine, is one of the most widely administered vaccines on the planet, given to over 100 million newborns each year. Its protection against pulmonary TB in adults is famously variable, ranging from near-zero in some tropical trials to about 80 percent in others. But BCG has drawn renewed interest for a different reason: its apparent ability to protect against infections that have nothing to do with tuberculosis.

This phenomenon, sometimes called trained immunity, appears to work through the innate immune system. BCG primes innate immune cells such as monocytes and natural killer cells through epigenetic and metabolic reprogramming, making them more responsive to a range of subsequent infections. Research has shown beneficial effects not only against respiratory viruses but also in bladder cancer treatment and even in reducing the incidence of type 1 diabetes.¹⁰ The idea that a vaccine could have broad protective effects beyond its target disease has significant implications for how we think about vaccination schedules in low-income countries where BCG is given early.

The Problem of Reversion

The central tradeoff of live vaccines is that the same ability to replicate that makes them so immunogenic also creates the possibility of the weakened pathogen evolving back toward virulence. This is called reversion, and it is the issue that most distinguishes live vaccines from their inactivated and subunit competitors.¹¹

The best-known example is oral polio vaccine. In rare circumstances, the weakened poliovirus in OPV mutates as it passes through a community, eventually regaining the ability to cause paralysis. These circulating vaccine-derived polioviruses (cVDPVs) have caused outbreaks, mostly in areas with low vaccination coverage. A newer formulation, novel oral polio vaccine type 2 (nOPV2), was engineered with genetic safeguards to make reversion harder. Early field data suggest it produces vaccine-derived emergences at roughly one-tenth the rate of the older formulation, approximately one emergence per 100 million doses compared to one per 10 million.¹²

Reversion has been demonstrated in laboratory settings with other viruses as well. When a SARS-CoV strain that had been attenuated by deleting its envelope protein gene was serially passaged through mice, it acquired a compensatory mutation and regained the ability to cause severe disease and death in the animals.¹³ Results like these underscore why modern vaccine design increasingly focuses on building multiple genetic barriers to reversion rather than relying on a single attenuation point.

Who Should Not Receive Live Vaccines

Because live vaccines contain replicating organisms, they are generally contraindicated for people whose immune systems cannot control the vaccine strain. This includes individuals on high-dose immunosuppressive drugs, organ transplant recipients on anti-rejection therapy, people undergoing chemotherapy, and those with severe primary immune deficiencies. Pregnant women are also advised to avoid live vaccines because of the theoretical risk of fetal infection.

A systematic review of safety data found that when immunocompromised people did receive live vaccines, the rate of side effects was only slightly higher than in healthy recipients or placebo groups. Severe complications and deaths were infrequent and occurred primarily in cancer patients in case reports rather than controlled studies.¹⁴ A Japanese review found that among immunosuppressed patients who were vaccinated, about 1 percent became infected with the vaccine virus strain, almost all with varicella, but none had life-threatening complications. Under carefully monitored immunological criteria, including adequate CD4 cell counts and normal immunoglobulin levels, live vaccines could be given safely even to children on immunosuppression.¹⁵

This does not mean immunocompromised people should go get MMR on their own. It means the blanket contraindication may be more conservative than it needs to be for some patients, and clinicians are beginning to evaluate risk on a case-by-case basis rather than applying an absolute ban.

Timing Around Maternal Antibodies

One practical wrinkle with live vaccines is their interaction with maternal antibodies. Babies are born with antibodies passed from their mother across the placenta, and these provide short-term protection during the first weeks and months of life.¹⁶ The catch is that those same maternal antibodies can neutralize the weakened vaccine virus before the baby’s own immune system has a chance to respond to it. This is a well-documented phenomenon across many vaccines and is the primary reason the first dose of MMR is scheduled at 12 months in most countries rather than earlier.¹⁷ In outbreak settings, measles vaccine can be given as early as 6 months, but a repeat dose is still needed later because the earlier dose is less likely to take.

The Cold Chain Challenge

Live vaccines are inherently fragile. The virus or bacterium in the vial must remain alive and able to replicate when it reaches the patient, which means temperature excursions during shipping and storage can ruin a batch. This dependency on continuous refrigeration, known as the cold chain, is one of the biggest logistical barriers to vaccination in low-resource settings. The yellow fever vaccine, for instance, must typically be kept frozen, while most other live vaccines require storage between 2°C and 8°C.

Formulation strategies like lyophilization (freeze-drying) help, but the underlying problem is that keeping a living organism stable at room temperature is genuinely hard.¹⁸ Researchers have been exploring novel thin-film platforms that can preserve live viruses, bacteria, and antibodies at ambient temperature for extended periods. One approach demonstrated that a recombinant adenovirus could survive 16 freeze-thaw cycles when embedded in an optimized thin-film formulation, opening the door to vaccines that could potentially be distributed without refrigeration.¹⁹ If technologies like these mature, they could dramatically expand access in tropical regions where maintaining a cold chain is expensive and unreliable.

How Live Vaccines Are Made Weaker in the First Place

The classical method of attenuation is blunt but effective: you grow the pathogen in cell culture or animal cells over many, many passages until it adapts to those laboratory conditions and loses its ability to cause disease in humans. The measles vaccine strain has been passaged through chick embryo cells. The oral polio vaccine strains were passaged through monkey kidney cells. The principle is that the virus accumulates mutations that make it better at growing in the lab environment and worse at thriving in the human body.

This approach still works. A recent study attenuated a virulent porcine deltacoronavirus by passaging it 240 times in pig kidney cells, at which point it was completely non-pathogenic in newborn piglets and provided full protection against challenge with the original virulent strain.²⁰ The downside is unpredictability: you do not fully control which mutations accumulate, and some of those mutations may be only a few reversions away from restoring virulence, as discussed earlier with polio.

mRNA and Subunit Alternatives Gaining Ground

Live vaccines are no longer the only game in town for strong, lasting immunity. The success of mRNA vaccines during the COVID-19 pandemic has accelerated work on mRNA-based replacements for diseases traditionally covered by live vaccines. In a head-to-head comparison in nonhuman primates, an mRNA vaccine encoding the varicella-zoster virus glycoprotein E produced immune responses comparable to the adjuvanted protein subunit vaccine (Shingrix) and markedly higher than those from the live attenuated varicella vaccine.²¹ The antibody decay rates were similar across all three platforms, meaning the mRNA and subunit vaccines could potentially offer longer-lasting protection simply because they started from a higher peak.

This does not mean live vaccines are obsolete. They remain superior for inducing mucosal immunity, they are often cheaper to produce, and for diseases like measles, the existing live vaccines already work so well that replacing them would be hard to justify on efficacy grounds. But for immunocompromised populations who cannot receive live vaccines, and for diseases where reversion risk is a genuine concern, non-replicating alternatives are increasingly attractive. The trajectory in vaccinology is toward a broader toolkit rather than wholesale replacement.

Public Perception and the “Live Virus” Label

The phrase “live virus” can alarm people who do not realize the vaccine virus is weakened to the point where it cannot cause full disease. In focus groups conducted in the Democratic Republic of the Congo, Kenya, and Nigeria around the introduction of the novel oral polio vaccine (nOPV2), all stakeholder groups anticipated initial hesitancy and suspicion from caregivers. Concerns centered on safety, side effects, and whether the vaccine had been adequately tested. The term “genetic modification” in particular was flagged as potentially controversial, even though the modifications were specifically designed to make the vaccine safer by reducing reversion risk.²²

The irony is that the engineering behind nOPV2 exists precisely because public-health experts listened to the concern about vaccine-derived polio. The older oral vaccine’s ability to revert was a known problem, and the newer version was built to fix it. Communicating that story clearly, rather than hiding behind technical jargon, turns out to be one of the harder parts of deploying a live vaccine in the real world.